Hims & Hers Health faces investigation over allegedly misleading statements.
PorAinvest
miércoles, 9 de julio de 2025, 9:39 am ET1 min de lectura
HIMS--
The investigation centers on Hims & Hers' handling of GLP-1 receptor agonists, particularly semaglutide. Novo Nordisk, the manufacturer of semaglutide, terminated its collaboration with Hims & Hers due to concerns over illegal mass compounding and deceptive marketing practices [2]. The FDA has warned against unapproved ingredients and counterfeit products in compounded GLP-1s, emphasizing patient safety risks [3].
In response to the termination, shares of Hims & Hers fell by 31.7% in afternoon trading on June 23, 2025 [1]. The FDA has resolved the Wegovy shortage by concluding that Novo Nordisk is fully meeting current and projected nationwide demand for the medicine [2]. To transition patients from knock-off compounded versions to authentic, FDA-approved Wegovy, Novo Nordisk has initiated a collaboration with telehealth companies, including Hims & Hers. However, Hims & Hers has failed to adhere to the law, which prohibits mass sales of compounded drugs under the guise of 'personalization' and has been disseminating deceptive marketing that puts patient safety at risk [1].
If you are a shareholder who suffered a loss, the DJS Law Group encourages you to contact them to discuss your rights [1].
References:
[1] https://www.prnewswire.com/news-releases/hims--hers-health-inc-investigated-for-securities-fraud-violations---contact-the-djs-law-group-to-discuss-your-rights--hims-302500946.html
[2] https://www.morningstar.com/news/pr-newswire/20250709la26723/hims-hers-health-inc-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-hims
[3] https://www.pharmacytimes.com/view/novo-nordisk-drops-hims-hers-inside-the-compounded-glp-1-crisis
MORN--
NVO--
OGN--
• Hims & Hers Health under investigation for securities violations • Allegations of misleading statements and undisclosed information • Novo Nordisk terminates collaboration due to illegal mass compounding and deceptive marketing • FDA resolved Wegovy shortage based on meeting nationwide demand • Transitioning patients to authentic Wegovy through NovoCare Pharmacy
Hims & Hers Health, Inc. (NYSE: HIMS), a telehealth company specializing in men's and women's health, is under investigation for potential securities violations. The DJS Law Group has announced it is investigating claims on behalf of Hims & Hers investors, alleging the company issued misleading statements and failed to disclose pertinent information [1].The investigation centers on Hims & Hers' handling of GLP-1 receptor agonists, particularly semaglutide. Novo Nordisk, the manufacturer of semaglutide, terminated its collaboration with Hims & Hers due to concerns over illegal mass compounding and deceptive marketing practices [2]. The FDA has warned against unapproved ingredients and counterfeit products in compounded GLP-1s, emphasizing patient safety risks [3].
In response to the termination, shares of Hims & Hers fell by 31.7% in afternoon trading on June 23, 2025 [1]. The FDA has resolved the Wegovy shortage by concluding that Novo Nordisk is fully meeting current and projected nationwide demand for the medicine [2]. To transition patients from knock-off compounded versions to authentic, FDA-approved Wegovy, Novo Nordisk has initiated a collaboration with telehealth companies, including Hims & Hers. However, Hims & Hers has failed to adhere to the law, which prohibits mass sales of compounded drugs under the guise of 'personalization' and has been disseminating deceptive marketing that puts patient safety at risk [1].
If you are a shareholder who suffered a loss, the DJS Law Group encourages you to contact them to discuss your rights [1].
References:
[1] https://www.prnewswire.com/news-releases/hims--hers-health-inc-investigated-for-securities-fraud-violations---contact-the-djs-law-group-to-discuss-your-rights--hims-302500946.html
[2] https://www.morningstar.com/news/pr-newswire/20250709la26723/hims-hers-health-inc-investigated-for-securities-fraud-violations-contact-the-djs-law-group-to-discuss-your-rights-hims
[3] https://www.pharmacytimes.com/view/novo-nordisk-drops-hims-hers-inside-the-compounded-glp-1-crisis
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios